LL-37: The Human Cathelicidin Antimicrobial Peptide

**Disclaimer:** This article is provided for educational and research purposes only. LL-37 is a research peptide that has not been approved by the FDA for therapeutic use. Viking Labs does not sell LL-37. Nothing in this article constitutes medical advice. All references are to published research.

Introduction

LL-37 is the sole cathelicidin antimicrobial peptide (AMP) produced by humans. Named for its 37-amino acid length and its two N-terminal leucine residues, LL-37 is cleaved from its precursor protein hCAP-18 (human cationic antimicrobial protein of 18 kDa) by proteinase 3, a serine protease present in neutrophil azurophilic granules. While many mammalian species express multiple cathelicidins, Homo sapiens relies on this single peptide as a first-line defense molecule of the innate immune system.

LL-37 is expressed in neutrophils, monocytes, macrophages, mast cells, and epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital tract. Its expression is constitutive in some tissues and inducible in others, with upregulation occurring in response to infection, inflammation, and --- notably --- vitamin D signaling. The discovery of the vitamin D-LL-37 axis by Liu et al. (2006) provided a molecular explanation for the long-observed association between vitamin D deficiency and susceptibility to infectious diseases, particularly tuberculosis.

Structure and Biophysical Properties

LL-37 adopts an amphipathic alpha-helical conformation in the presence of biological membranes or membrane-mimetic environments. The peptide carries a net positive charge of +6 at physiological pH, arising from six lysine and five arginine residues distributed along its length. This cationic character is essential for its initial electrostatic attraction to negatively charged bacterial membrane surfaces.

In aqueous solution, LL-37 exists in a largely unstructured conformation. Upon interaction with lipid membranes or at elevated concentrations, the peptide undergoes a coil-to-helix transition, forming a continuous alpha-helix spanning residues 2 through 31, with a flexible C-terminal tail. This structural transition is critical for biological activity: the helical conformation positions hydrophobic residues along one face and hydrophilic/cationic residues along the opposite face, creating the amphipathic architecture required for membrane insertion and disruption.

X-ray crystallography studies by Sancho-Vaello et al. (2017) revealed that LL-37 forms oligomeric assemblies, with four peptide molecules arranged as two antiparallel dimers creating a fiber-like supramolecular structure. This oligomerization is concentration-dependent and may be relevant to the peptide's pore-forming activity and its ability to coat and neutralize bacterial surfaces.

Antimicrobial Mechanism: Membrane Disruption

The primary antimicrobial mechanism of LL-37 involves direct disruption of microbial membranes. The selectivity of LL-37 for bacterial over mammalian membranes arises from fundamental differences in membrane composition. Bacterial membranes are rich in negatively charged phospholipids (phosphatidylglycerol, cardiolipin) and lipopolysaccharide (Gram-negative) or lipoteichoic acid (Gram-positive), providing abundant electrostatic binding sites for cationic peptides. Mammalian cell membranes, by contrast, have an outer leaflet composed predominantly of zwitterionic phospholipids (phosphatidylcholine, sphingomyelin) and cholesterol, presenting a much weaker electrostatic target.

Upon binding to bacterial membranes, LL-37 is thought to operate through the "toroidal pore" or "carpet" model of membrane disruption. At sub-critical concentrations, peptide molecules accumulate on the membrane surface in a carpet-like fashion, oriented parallel to the lipid bilayer. At threshold concentrations, the accumulated peptides insert into the membrane and induce curvature strain, leading to the formation of transient toroidal pores through which ions and small molecules leak. At higher concentrations, the membrane is catastrophically disrupted, leading to cell lysis.

LL-37 demonstrates broad-spectrum antimicrobial activity in vitro against both Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis) and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae), as well as against certain fungi (Candida albicans) and enveloped viruses. Minimum inhibitory concentrations (MICs) typically range from 1 to 32 micromolar depending on the organism, growth conditions, and salt concentration.

An important caveat is that LL-37's direct antimicrobial activity is substantially reduced at physiological salt concentrations (approximately 150 mM NaCl), as sodium and divalent cations compete with the peptide for electrostatic binding sites on bacterial surfaces. This observation has led researchers to conclude that direct antimicrobial killing, while significant in low-salt environments such as sweat and airway surface liquid, may be less important than the peptide's immunomodulatory functions in physiological settings.

Biofilm Disruption

One of the most clinically relevant properties of LL-37 is its ability to disrupt bacterial biofilms. Biofilms --- structured microbial communities encased in a self-produced extracellular matrix --- are resistant to conventional antibiotics and host immune defenses and are implicated in chronic infections of wounds, prosthetic devices, and the respiratory tract.

Overhage et al. (2008) demonstrated that LL-37 inhibits Pseudomonas aeruginosa biofilm formation at sub-MIC concentrations (as low as 0.5 micromolar) through multiple mechanisms: suppression of initial bacterial attachment, stimulation of twitching motility (which disrupts microcolony architecture), downregulation of quorum-sensing gene expression, and direct degradation of pre-formed biofilm matrix. Importantly, these anti-biofilm effects occurred at concentrations well below those required for direct killing, suggesting that biofilm disruption and bactericidal activity are mechanistically distinct.

Dean et al. (2011) extended these findings to Staphylococcus aureus biofilms, showing that LL-37 fragments (particularly the central helical domain, residues 17-29) retained anti-biofilm activity while exhibiting reduced hemolytic toxicity compared to the full-length peptide. This observation has informed the design of truncated LL-37 derivatives optimized for anti-biofilm applications.

Immunomodulatory Functions

Beyond direct antimicrobial activity, LL-37 functions as a potent immunomodulator, influencing both innate and adaptive immune responses through multiple mechanisms.

Chemotaxis: LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through activation of the formyl peptide receptor-like 1 (FPRL1, also known as FPR2/ALX). This receptor-mediated chemotaxis facilitates the recruitment of immune cells to sites of infection and tissue damage. Yang et al. (1999) first demonstrated this chemotactic activity and identified FPRL1 as the relevant receptor.

Cytokine modulation: LL-37 modulates cytokine production in a context-dependent manner. It can enhance the production of pro-inflammatory cytokines (IL-8, MCP-1) in epithelial cells through activation of MAPK and NF-kB pathways, while simultaneously suppressing the production of pro-inflammatory cytokines in macrophages stimulated with bacterial lipopolysaccharide (LPS). This dual activity suggests that LL-37 promotes appropriate immune activation while preventing excessive inflammatory responses that could cause tissue damage.

Danger signal amplification: Lande et al. (2007) demonstrated that LL-37 binds self-DNA released from dying cells, forming complexes that trigger type I interferon production in plasmacytoid dendritic cells through TLR9 activation. This mechanism has been implicated in psoriasis pathogenesis, where LL-37-DNA complexes drive pathological interferon signaling.

Wound Healing

LL-37 promotes wound healing through mechanisms that extend beyond its antimicrobial and immunomodulatory activities. Heilborn et al. (2003) demonstrated that LL-37 is highly expressed in wound-edge keratinocytes during the early phases of healing and that the peptide directly stimulates keratinocyte migration and proliferation through transactivation of the epidermal growth factor receptor (EGFR).

The mechanism involves LL-37-mediated release of heparin-binding EGF-like growth factor (HB-EGF) from the cell surface through activation of metalloproteinases, leading to autocrine/paracrine EGFR signaling. This transactivation pathway promotes re-epithelialization --- the migration of epithelial cells across the wound bed to restore barrier function.

Additionally, LL-37 promotes angiogenesis in healing tissues. Koczulla et al. (2003) showed that LL-37 stimulates endothelial cell proliferation and vessel formation in a FPRL1-dependent manner. In vivo, application of LL-37 to rabbit wounds increased vascular density in granulation tissue compared to controls.

The Vitamin D Connection

The discovery that LL-37 expression is regulated by vitamin D has had profound implications for understanding the role of this peptide in human health. Liu et al. (2006) demonstrated that activation of Toll-like receptors on human macrophages by Mycobacterium tuberculosis components triggers upregulation of the vitamin D receptor (VDR) and the CYP27B1 enzyme (which converts 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D). Active vitamin D then binds the VDR, which acts as a transcription factor to induce CAMP gene expression (encoding hCAP-18/LL-37).

This pathway provides a direct molecular link between vitamin D status and innate antimicrobial defense. Individuals with vitamin D deficiency produce less LL-37 and demonstrate impaired antimicrobial responses, particularly against intracellular pathogens such as M. tuberculosis. Supplementation with vitamin D has been shown to restore LL-37 expression in vitamin D-deficient individuals, though the clinical impact of this restoration on infection outcomes remains under active investigation.

Challenges and Therapeutic Development

Therapeutic development faces several challenges: proteolytic degradation in biological fluids, reduced activity at physiological salt concentrations, potential cytotoxicity at high doses, and the psoriasis-related immunopathology risk. Current research focuses on LL-37 derivatives using truncated peptides, D-amino acid substitutions, cyclization, and nanoparticle delivery systems to overcome these limitations.

Summary

LL-37, the sole human cathelicidin, is a multifunctional host defense peptide that bridges innate immunity, wound healing, and antimicrobial defense. Its mechanisms span direct membrane disruption of pathogens, biofilm interference, immune cell recruitment, cytokine modulation, and growth factor signaling. The vitamin D-LL-37 axis connects nutritional status to immune competence at a molecular level. While therapeutic development faces pharmacokinetic and safety challenges, LL-37 and its derivatives remain active areas of research for antibiotic-resistant infections and chronic wound management.

*This article is provided for informational and research purposes only. Viking Labs does not sell LL-37. Nothing in this article should be construed as medical advice.*